Incyte/Merck's ECHO-301 Failure Casts More Shadow On IDO Space
Following failure of Incyte/Merck's epacadostat/Keytruda study, NewLink Genetics says it is reviewing its IDO clinical programs.
You may also be interested in...
Incyte's hopes of reducing its reliance on Jakafi have suffered a blow after a Phase III trial of itacitinib failed. The stock has slumped and analysts are raising concerns about the company's ability to generate value from its hefty R&D investments.
The US biotech’s product becomes the first glutaminase inhibitor to show proof of concept. Calithera now awaits data from a larger registrational study next year in renal cell carcinoma.
In an audio interview from the recent ASCO-SITC meeting, Chen weighs in on comparisons of PD-1 and PD-L1 inhibitors, the IDO failures, biomarkers and his new work at the private biotech IGM Biosciences.